1995
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
Schoen R, Meurice F, Brunet C, Cretella S, Krause D, Craft J, Fikrig E. Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease. The Journal Of Infectious Diseases 1995, 172: 1324-1329. PMID: 7594671, DOI: 10.1093/infdis/172.5.1324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, BacterialAntibody FormationAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansImmunization ScheduleImmunoglobulin GLipoproteinsLyme DiseaseProspective StudiesSafetyVaccines, SyntheticConceptsSide effectsLyme diseaseOspA vaccinePrevious Lyme diseaseThree-dose scheduleLocal side effectsSystemic side effectsLyme vaccineMild arthralgiaVaccine doseThird doseProspective studyOspA antibodiesHealthy volunteersOuter surface proteinsVaccinePatientsDiseaseImmunogenicityDoseMonthsSubjectsSurface proteinsSafetyArthralgia
1986
Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.
Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. Journal Of Clinical Investigation 1986, 78: 934-939. PMID: 3531237, PMCID: PMC423723, DOI: 10.1172/jci112683.Peer-Reviewed Original ResearchConceptsIgG responsesIgM responseEarly diseaseLyme diseaseImmunoglobulin M responseImmunoglobulin G responseBorrelia burgdorferiSpirochetal antigensG responsesIgG antibodiesProlonged illnessPatientsM responseIllnessDiseaseAntigenB. burgdorferiMonthsLimited responseIgMBurgdorferiSuch responsesResponseArthritisYears